Continuing the recent interview with Henry Doss, ecosystem architect and co-author of ‘The Rainforest Scorecard: A Practical Framework for Growing Innovation Potential', we now look more closely at the elements of engineering a culture of innovation.
Dr Robert Langer was the recent recipient of the Queen Elizabeth Prize in Engineering, for his groundbreaking research into controlled, targeted drug delivery. eyeforpharma unravels his past achievements, discusses his present research and offers his future vision of medicine.
US President Barack Obama recently pledged $215m for his precision medicine initiative. Danielle Barron discusses the future of precision medicine with InnVentis founder and CEO Thomas Wilckens, and examines the impact this will have on the current R&D environment.
Dr Vivienne van de Walle offers 9 steps pharma companies can take to improve clinical trials based on her own insights and conversations with other investigators, who agree that using eClinical technologies to collect patient data can improve compliance and data quality, and reduce monitoring time.
We report on some of the key debates taking centre stage at the 8th Pharmacovigilance Conference, held recently, including the implications of emerging markets, utilizing new and emerging technologies, risk management strategies, and shifting towards patient-centricity.
Danielle Barron talks to author Ron Adner whose book “The Wide Lens” explains why the failure to focus on the entire ecosystem rather than the immediate environment of a new product is the downfall of pharmaceutical companies attempting to successfully commercialize innovation.
With a staggering cost of drug development estimated at US$2.6 billion and a high failure rate of new compounds, pharma is under pressure to develop solutions that improve the R&D hit rate. Real World Evidence combined with digital healthcare might be what the industry is looking for.